- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.04. | Sumitomo Pharma's stem cell therapy for Parkinson's given limited approval in Japan | ||
| 17.04. | Allergan Aesthetics launches Skin Quality Index for aesthetic consultations | ||
| 16.04. | AC Immune amends agreement with Lilly to develop potential Alzheimer's treatment | ||
| 16.04. | Bowel Research UK appoints Kathryn Pretzel-Shiels as CEO | ||
| 15.04. | EMA's PRIME scheme launches three major new features | ||
| 14.04. | Annovis partners with NeuroRPM on new AI platform to track Parkinson's symptoms | ||
| 14.04. | START partners with Trialing to expand patient access to oncology clinical trials across Europe | ||
| 13.04. | Bristol Myers Squibb evolves and expands multiple myeloma programme | ||
| 13.04. | One-carbon Therapeutics collaborates with Tempus in cancer treatment | ||
| 10.04. | Lilly to acquire Centessa in deal worth up to $7.8bn | ||
| 10.04. | Takeda's CEO-elect, Julie Kim, proposed as new candidate for Board of Directors | ||
| 09.04. | Biogen to acquire Apellis in $5.6bn deal | ||
| 09.04. | Matt Ferriday announced as General Manager for LEO Pharma UK | ||
| 08.04. | Gilead to acquire Tubulis for up to $5bn | ||
| 08.04. | Pistoia Alliance publishes first best-practice framework for ethical social media use in drug development | ||
| 07.04. | Lilly's Foundayo approved by US FDA as oral GLP-1 for weight loss | ||
| 07.04. | Marking World Health Day on 7 April | ||
| 02.04. | Roche opens new Swiss Institute of Human Biology research facility | ||
| 02.04. | ReproNovo appoints Mark Altmeyer as Chairman of the Board | ||
| 01.04. | Novartis to acquire Excellergy in deal worth up to $2bn | ||
| 01.04. | Poolbeg Pharma appoints Adrian Kilcoyne to Scientific Advisory Board | ||
| 31.03. | Pharma's content paradox: why more content is not the answer | ||
| 31.03. | Achieving comms excellence through personalised engagement | ||
| 31.03. | Novo Nordisk's Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes | ||
| 31.03. | Sandoz partners with Samsung Bioepis to develop up to five biosimilars |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.